NDA 217417 · Mundipharma
Rezzayo
Rezafungin Acetate · Intravenous · Echinocandin Antifungal
NovelPriority reviewOrphanCDER novel approval, Mar 22, 2023: To treat candidemia and invasive candidiasis
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 22, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 1 recruiting
FAERS reports
101
46 serious, 18 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2026.
REZZAYO is an echinocandin antifungal indicated in adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) 1.1 Treatment of Candidemia and Invasive Candidiasis REZZAYO is indicated in adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis [see Microbiology ( 12.4 )] . Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO [see Clinical Studies ( 14 )] . Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida . 1.2 Usage Specimens for culture and other laboratory data (e.g., histopathology, non-culture diagnostics) should be obtained prior to initiating antifungal therapy. Therapy may be initiated before the results of the cultures and other laboratory tests are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Mechanism: Rezafungin is an echinocandin antifungal drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Rezafungin" as an intervention, any sponsor and status, largest first.
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationPivotal-lookingCompleted
Mundipharma Research LimitedIndustry
NCT04368559 · 602 participants · Start May 11, 2020 · Primary completion Jan 29, 2026
Drug: Rezafungin for Injection; Posaconazole and 4 more · For: Candidemia; Mycoses; Fungal Infection and 7 more
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 53 sites in all
- Rezafungin Prophylaxis in Liver TransplantPivotal-lookingEnrolling by invitation
Fernanda P Silveira, MD, MSAcademic, hospital or other
NCT06774144 · 385 participants (planned) · Start Oct 15, 2025 · Primary completion Dec 2028
Drug: Rezafungin; Standard of care antifungal prophylaxis · For: Liver Transplant Infection; Fungal Infection
Sites: Pittsburgh, Pennsylvania
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisPivotal-lookingCompleted
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT03667690 · 199 participants · Start Oct 7, 2018 · Primary completion Oct 7, 2021
Drug: Rezafungin for Injection; Caspofungin and 3 more · For: Candidemia; Mycoses; Fungal Infection and 1 more
Sites: Birmingham, Alabama; Sacramento, California; Atlanta, Georgia · 132 sites in all
- Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsActive, not recruiting
Mundipharma Research LimitedIndustry
NCT06794554 · 60 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 30, 2026
Drug: Rezafungin Acetate · For: Chronic Pulmonary Aspergillosis
Sites: Linz, Austria; Brussels, Belgium; Ghent, Belgium · 37 sites in all
Mundipharma Research LimitedIndustry
NCT05835479 · 50 participants (planned) · Start Nov 14, 2023 · Primary completion May 2025
Drug: Co-Trimoxazole; Rezafungin Acetate / Co Trimoxazole · For: Pneumocystis Pneumonia
Sites: Cape Town, South Africa; Johannesburg, South Africa; Pretoria, South Africa · 6 sites in all
Mundipharma Research LimitedIndustry
NCT05534529 · 32 participants · Start Sep 13, 2023 · Primary completion May 23, 2024
Drug: Rezafungin Acetate · For: Invasive Fungal Infections
Sites: Essen, Germany; Frankfurt, Germany; Münster, Germany · 10 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04117607 · 14 participants · Start Dec 4, 2019 · Primary completion May 11, 2020
Drug: Rezafungin; Rezafungin · For: Fungal Infection
Sites: San Antonio, Texas
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
NCT06985758 · 12 participants · Start Jan 7, 2026 · Primary completion May 31, 2026
Drug: Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg · For: Candidal Peritonitis
Sites: Madrid, Spain; Valencia, Spain · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rezzayo (Rezafungin Acetate)
2024 spending
$161K
Beneficiaries
20
61 claims
Per beneficiary
$8,045
$1,962.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $60,944 |
| 2024 | $160,895 |
Part B: Rezzayo (Rezafungin Acetate) · HCPCS J0349
2024 spending
$1.1M
Beneficiaries
107
407 claims
Per beneficiary
$10,282
2024 ASP limit $10.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $128,316 |
| 2024 | $1,100,129 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR, Soriano A, Cornely OA, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR, Soriano A, Honore PM, et al. · Lancet Infect Dis 2024 · Multicenter Study, Randomized Controlled Trial
- Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Thompson GR, Soriano A, Skoutelis A, et al. · Clin Infect Dis 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials.
Honoré PM, Bassetti M, Cornely OA, et al. · Crit Care 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.
Flanagan S, Goodman DB, Jandourek A, et al. · Clin Pharmacol Drug Dev 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
- Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
Honoré PM, Girardis M, Kollef M, et al. · Crit Care 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Mundipharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.